School of Pharmacy, University of Auckland, Auckland, New Zealand.
Waitematā District Health Board, Auckland, New Zealand.
Drugs Aging. 2021 Mar;38(3):205-217. doi: 10.1007/s40266-020-00828-0. Epub 2021 Jan 12.
In Aotearoa New Zealand (NZ), ethnic inequities in health outcomes exist. Non-Māori experience better access to healthcare than Māori, including access to the quality use of medicines. Quality medicines use requires that medicines provide maximal therapeutic benefit with minimal harm. As older adults are more at risk of harm from medicines, and, because inequities are compounded with age, Māori older adults may be at more risk of medicines-related harm than younger and non-Māori populations. This narrative review examined ethnic variation in the quality use of medicines, including medicines utilisation and associated clinical outcomes, between Māori and non-Māori older adult populations in NZ. The review was structured around prevalence of medicine utilisation by medicine class and in particular disease states; high-risk medicines; polypharmacy; prevalence of potentially inappropriate prescribing (PIP); and association between PIP and clinical outcomes. 22 studies were included in the review. There is ethnic variation in the access to medicines in NZ, with Māori older adults often having reduced access to particular medicine types, or in particular disease states, compared with non-Māori older adults. Māori older adults are less likely than non-Māori to be prescribed medicines inappropriately, as defined by standardised tools; however, PIP is more strongly associated with adverse outcomes for Māori than non-Māori. This review identifies that inequities in quality medicines use exist and provides a starting point to develop pro-equity solutions. The aetiology of inequities in the quality use of medicines is multifactorial and our approaches to addressing the inequitable ethnic variation also need to be.
在新西兰(NZ),存在健康结果的族裔不平等现象。非毛利人比毛利人更容易获得医疗保健,包括获得高质量的药物使用。高质量的药物使用要求药物在最小化伤害的情况下提供最大的治疗效益。由于老年人更容易受到药物的伤害,而且随着年龄的增长,不平等现象会加剧,毛利族老年人可能比年轻的和非毛利族人口更容易受到与药物相关的伤害。这篇叙述性评论检查了新西兰毛利族和非毛利族老年人群体在药物质量使用方面的族裔差异,包括药物利用和相关临床结果。该评论围绕着药物利用的流行程度进行组织,包括药物类别和特定疾病状态下的药物利用;高危药物;多种药物治疗;潜在不适当处方(PIP)的流行率;以及 PIP 与临床结果之间的关联。该评论纳入了 22 项研究。新西兰的药物获取存在族裔差异,毛利族老年人通常比非毛利族老年人获得某些药物类型或特定疾病状态的药物的机会减少。与非毛利族老年人相比,毛利族老年人不太可能被开具不适当的药物,这是由标准化工具定义的;然而,对于毛利族老年人来说,PIP 与不良后果的相关性比非毛利族老年人更强。本综述确定了在高质量药物使用方面存在不平等现象,并为制定公平的解决方案提供了起点。药物质量使用不平等的病因是多因素的,我们解决族裔不平等现象的方法也需要是多因素的。